When, if at all, is it appropriate to re-challenge a patient with a EGFR inhibitor in metastatic RAS/BRAF WT colon cancer?
Would sidedness matter? Do you use ctDNA assays to evaluate for acquired RAS mutations to guide this decision?
Community PollStarted
Do you re-challenge with EGFR inhibitors in metastatic RAS/BRAF WT colon ca?
49 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet Member
Medical Oncology · Mayo Clinic
Answered on
Following the MD Anderson data presented several years ago by Parseghian et al., PMID 30462160 regarding successful rechallenge after the resistant RAS/EGFR clones decay from detection in the blood, I do utilize ctDNA profiling primarily at times of progression with the intent of rechallenging. Anec...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic
Answered on
We have been encouraged by the CRICKET study, E-Rechallenge trial, and some other retrospective study data supporting the EGFRi rechallenge in patients with negative RAS/BRAF by ctDNA test. This has been used routinely in our clinic. Here is a nice review article that summarized the evidence we have...
Join for free or sign in to see the full answer